The results of the mutational analysis for patients in part 1 of the study revealed an increased frequency of mutations typically associated with MDS diagnosis, such as ASXL1, SRSF2, and TET2. [24] However, data were not sufficient to make conclusions on the relationship between the presence of mutations and clinical response. Here, SRSF2 is linked to myelodysplastic syndrome.